Chief Investment Strategist
Summary: A vaccine against COVID-19 is critical for society and to get the economy back on track. We've looked at the WHO's official list of 76 vaccine candidates being tested, found the companies involved with developing them and detailed those you can trade via Saxo's trading platform. The potential is big for the company that develops the right vaccine, but it also comes with very high risk.
Health experts agree that a vaccine is key to fighting the COVID-19 global pandemic and restoring life and the economy to what it was. The fastest vaccine ever developed in human history took four years, but the community of universities and biotechnology companies feel confident that through global collaboration a COVID-19 vaccine can be ready in 18 months. The race is on. The WHO published a list of 76 vaccine candidates on 20 April and this is now the official list. We have no knowledge of which company will win the race to find a vaccine against COVID-19. But we have found all the companies with Saxo ticker codes, so that it’s easier for you to identify the companies that can offer you exposure to this potential upside. It's important to recognise that investing in this opportunity comes with very high risk as some of the companies are illiquid and have small market values. But in general the risks of developing a vaccine are high, as you are competing against many other companies and universities. More importantly a vaccine is not just a vaccine as each comes with different coverage ratio of the various mutations but also with different risk profiles for the various age cohorts.
Companies on the WHO vaccine list, which you can trade via SaxoTraderGO, ordered by market cap.
| Saxo ticker | Company | Return YTD, pct. (LCY) | Mkt. cap (USD mn.) |
| PFE:xnys | Pfizer Inc | 0.1 | 215332 |
| MRNA:xnas | Moderna Inc | 144.7 | 17643 |
| 600196:xssc | Shanghai Fosun Pharmaceutical | 28.5 | 11685 |
| BNTX:xnas | BioNTech SE | 42.6 | 10960 |
| APDN:xnas | Takara Bio Inc | 23.0 | 2860 |
| 4563:xtks | AnGes Inc | 154.0 | 1881 |
| INO:xnas | Inovio Pharmaceuticals Inc | 205.5 | 1471 |
| NVAX:xnas | Novavax Inc | 333.2 | 999 |
| ARCT:xnas | Arcturus Therapeutics Holdings | 272.2 | 804 |
| DVAX:xnas | Dynavax Technologies Corp | -29.2 | 355 |
| VXRT:xnas | Vaxart Inc | 627.5 | 181 |
| IMV:xtse | IMV Inc | -25.5 | 110 |
| IBIO:xase | iBio Inc | 323.7 | 107 |
| ALT:xnas | Altimmune Inc | 61.9 | 47 |
| HTBX:xnas | Heat Biologics Inc | 15.1 | 45 |
| IPA:xtsx | ImmunoPrecise Antibodies Ltd | 32.8 | 38 |
| EXPRS2:xome | Expres2ion Biotech Holding AB | 380.7 | 30 |
For more coronavirus trading inspiration, check the coronavirus section in SaxoTraderGO.
Quarterly Outlook
Chief Investment Strategist
Quarterly Outlook
Head of Fixed Income Strategy
Quarterly Outlook
Chief Investment Strategist
Quarterly Outlook
Chief Investment Strategist
Quarterly Outlook
Head of Commodity Strategy
Quarterly Outlook
Chief Investment Strategist
Quarterly Outlook
Chief Investment Strategist
Quarterly Outlook
Chief Investment Strategist
Quarterly Outlook
Head of Fixed Income Strategy
Quarterly Outlook
Head of Commodity Strategy
Disclaimer
The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.
Please read our disclaimers:
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)
- Full disclaimer (https://www.home.saxo/en-gb/legal/disclaimer/saxo-disclaimer)